Acrivon Therapeutics, Inc.

ACRV

Held by 2 specialist biotech funds

Share on X

Fund Holdings

Baker Bros. Advisors RA Capital Management

AI Signal

## Baker Bros.

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Activist Filings

SC 13D/ARA Capital Management21.6%Mar 23, 2026

SC 13D/ARA Capital Management27.1%Apr 11, 2024

SC 13D/A

Position Details

Baker Bros. AdvisorsNEWFeb 17, 2026

Shares: 22,809Value: $55K

## Baker Bros. Takes New Position in Acrivon Therapeutics (ACRV) Baker Brothers initiated a $55M position in ACRV, a clinical-stage company developing ACR-368 (a selective ATR inhibitor with a proprietary OncoSignature patient-selection diagnostic) across multiple solid tumor indications including platinum-resistant ovarian cancer, endometrial, and other genomically defined cancers. This is a notably large initial position even by Baker standards and signals strong conviction in the precision oncology platform ahead of key clinical data readouts from the ongoing Phase 1/2 trials expected in 2025. Baker's concentrated, high-conviction style—combined with their deep diligence capabilities in biotech mechanisms of action—makes this a meaningful signal for a company whose patient-selection biomarker approach could de-risk the clinical path and differentiate ACR-368 in the competitive DDR space.

RA Capital ManagementNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

FDMT2 funds BCRX2 funds SION2 funds CTNM2 funds DSGN2 funds IRON2 funds EWTX2 funds SYRE

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

RA Capital's $20.1M debut position in ACRV signals conviction in the company's pipeline of selective estrogen receptor degraders (SERDs) for hormone-driven cancers, particularly its lead candidate AVT-246 in breast cancer. The timing suggests confidence ahead of near-term clinical readouts, likely Phase 2 data expected in late 2024/early 2025 that could position AVT-246 as a competitive alternative to established SERDs like fulvestrant. Kolchinsky's entry is notable given RA's track record in early-stage biotech, implying the risk-reward at current valuations (~$2.4B market cap) appears asymmetric relative to clinical/commercial milestones ahead.